Fulcrum Therapeutics Stock Forward View - Simple Exponential Smoothing
| FULC Stock | USD 7.65 0.02 0.26% |
Momentum
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter -0.29 | EPS Estimate Current Year -1.30 | EPS Estimate Next Year -1.60 | Wall Street Target Price 19 | EPS Estimate Current Quarter -0.30 |
This section provides headline-driven context for Fulcrum Therapeutics alongside peer activity. The sentiment layer reflects Fulcrum Therapeutics' options activity and short interest context.
Fulcrum Therapeutics Short Interest View
A sudden spike in Fulcrum Therapeutics' short interest may indicate that institutional investors have identified specific risks - such as earnings disappointments or regulatory events - not yet priced into the market.
200 Day MA 8.7814 | Short Percent 0.0843 | Short Ratio 4.99 | Shares Short Prior Month 3.5 M | 50 Day MA 9.8612 |
Fulcrum RSI Context
The Simple Exponential Smoothing forecasted value of Fulcrum Therapeutics on the next trading day is expected to be 7.65 with a mean absolute deviation of 0.32 and the sum of the absolute errors of 19.47.Fulcrum Therapeutics Hype-Price Relationship
Sentiment data for Fulcrum Therapeutics synthesizes media coverage, analyst tone, and social engagement into a single signal. When Fulcrum Therapeutics' sentiment diverges sharply from price, a mean-reversion trade may be developing.
For Fulcrum Therapeutics, sentiment analysis reveals whether the prevailing narrative matches business reality. A persistent divergence often resolves in the direction of fundamentals once sentiment normalizes.
Fulcrum Therapeutics Implied Volatility | 1.33 |
When Fulcrum Therapeutics' implied volatility is unusually high relative to its historical average, options premiums are inflated. Sophisticated investors may choose to sell options in this environment to collect elevated premium income.
The Simple Exponential Smoothing forecasted value of Fulcrum Therapeutics on the next trading day is expected to be 7.65 with a mean absolute deviation of 0.32 and the sum of the absolute errors of 19.47.Fulcrum Therapeutics after-hype prediction price | $ 8.03 |
The sentiment panel provides context that can be compared with forecasting models and technical indicators.
Historical Fundamental Analysis of Fulcrum Therapeutics can be used to cross-verify projections for Fulcrum Therapeutics. The historical series provides projection context.Rule 16 Overview for current Fulcrum contract - Risk Context
Rule 16 applies implied volatility to estimate a daily move of roughly 0.0831% across the 2026-06-18 option cycle. The figure is a neutral volatility reference; near $ 7.65, it implies about $ 0.006359 per day.
Open Interest Context: Fulcrum 2026-06-18 Options
Open interest represents the number of active Fulcrum Therapeutics option contracts and offers a participation signal.
Fulcrum Therapeutics Additional Predictive Modules
Most predictive techniques to examine Fulcrum price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Fulcrum using various technical indicators. When you analyze Fulcrum charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Simple Exponential Smoothing Price Forecast For the 16th of March 2026
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of Fulcrum Therapeutics on the next trading day is expected to be 7.65 with a mean absolute deviation of 0.32 , mean absolute percentage error of 0.23 , and the sum of the absolute errors of 19.47 .Please note that although there have been many attempts to predict Fulcrum Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Fulcrum Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Fulcrum Therapeutics | Fulcrum Therapeutics Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Fulcrum Therapeutics uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Fulcrum Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Fulcrum Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 114.7936 |
| Bias | Arithmetic mean of the errors | 0.0927 |
| MAD | Mean absolute deviation | 0.3246 |
| MAPE | Mean absolute percentage error | 0.0323 |
| SAE | Sum of the absolute errors | 19.4744 |
The mean reversion effect in Fulcrum Therapeutics is stronger when the initial deviation was driven by sentiment rather than fundamental change. Identifying the root cause of Fulcrum Therapeutics' price dislocation is essential before acting.
After-Hype Price Density Analysis
The probability distribution for Fulcrum Therapeutics' predicted price encodes the full spectrum of outcomes, weighted by their estimated likelihood. Investors should compare this range against their personal risk tolerance before committing to Fulcrum Therapeutics positions.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
The news prediction model for Fulcrum Therapeutics analyzes the correlation between Fulcrum Therapeutics' historical headline events and same-day or next-day price movements. Fulcrum Therapeutics' after-hype downside and upside margins for the prediction period are 3.58 and 12.48, respectively. Predictive accuracy varies significantly across different news categories and market regimes for Fulcrum Therapeutics.
Current Value
The after-hype framework applied to Fulcrum Therapeutics assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Fulcrum Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fulcrum Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Fulcrum Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.74 | 4.45 | 0.38 | 0.03 | 9 Events | 8 Events | In 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
7.65 | 8.03 | 4.97 |
|
Hype Timeline
Fulcrum Therapeutics is currently traded for 7.65. The company has historical hype elasticity of 0.38, and average elasticity to hype of competition of -0.03. Fulcrum is expected to increase in value after the next headline, with the price projected to jump to 8.03 or above. The average volatility of media hype impact on the company the price is over 100%. The price growth on the next news is projected to be 4.97%, whereas the daily expected return is currently at -0.74%. The volatility of related hype on Fulcrum Therapeutics is about 11710.53%, with the expected price after the next announcement by competition of 7.62. Fulcrum Therapeutics currently holds about 221.79 M in cash with -60.06 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26. Given the investment horizon of 90 days the next expected press release will be in 9 days. Historical Fundamental Analysis of Fulcrum Therapeutics can be used to cross-verify projections for Fulcrum Therapeutics. The historical series provides projection context.Related Hype Analysis
Sector-wide news events often affect Fulcrum Therapeutics before the fundamental impact on Fulcrum Therapeutics' own business becomes clear. Peer hype analysis helps investors distinguish between sector-level sentiment shifts and Fulcrum Therapeutics-specific developments.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| OCGN | Ocugen Inc | 0.04 | 8 per month | 4.89 | 0.21 | 8.54 | -7.47 | 32.50 | |
| CMPX | Compass Therapeutics | -0.25 | 9 per month | 2.99 | 0.01 | 6.27 | -5.14 | 18.15 | |
| LXRX | Lexicon Pharmaceuticals | 0.10 | 8 per month | 4.82 | 0.09 | 9.17 | -7.09 | 38.53 | |
| OMER | Omeros | -0.17 | 9 per month | 4.56 | 0.04 | 4.80 | -7.14 | 87.69 | |
| RAPT | RAPT Therapeutics | -0.01 | 8 per month | 2.33 | 0.14 | 7.76 | -6.37 | 64.19 | |
| NMRA | Neumora Therapeutics | 0.04 | 17 per month | 3.56 | 0.11 | 10.98 | -7.10 | 34.13 | |
| BCYC | Bicycle Therapeutics | 0.17 | 6 per month | 0.00 | -0.18 | 4.64 | -5.65 | 13.61 | |
| LCTX | Lineage Cell Therapeutics | 0.04 | 7 per month | 0.00 | 0.01 | 4.65 | -5.64 | 21.47 | |
| ADCT | ADC Therapeutics SA | 0.30 | 8 per month | 3.36 | 0.11 | 8.03 | -5.41 | 24.46 | |
| NGNE | Neurogene | -0.64 | 9 per month | 3.98 | 0.04 | 8.73 | -6.83 | 31.07 |
Other Forecasting Options for Fulcrum Therapeutics
For both new and experienced investors in Fulcrum, the ability to analyze Fulcrum Therapeutics' price movement is a fundamental investment skill. Price chart noise in Fulcrum Stock can create false signals and mislead investment decisions.Fulcrum Therapeutics Related Equities
The following equities are related to Fulcrum Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Fulcrum Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Fulcrum Therapeutics Market Strength Events
Tracking market strength indicators for Fulcrum Therapeutics helps investors understand the momentum dynamics of the stock in real time. These signals support informed decisions about when to enter or exit positions in Fulcrum Therapeutics for maximum return potential.
Fulcrum Therapeutics Risk Indicators
Properly assessing Fulcrum Therapeutics' risk indicators is a prerequisite for building reliable price forecasts. Identifying and quantifying the risks associated with Fulcrum Therapeutics' allows investors to make better-informed decisions about accepting or hedging their exposure.
| Mean Deviation | 3.37 | |||
| Standard Deviation | 4.73 | |||
| Variance | 22.34 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Fulcrum Therapeutics
Coverage intensity for Fulcrum Therapeutics matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Fulcrum Therapeutics Short Properties
Short sentiment tied to Fulcrum Therapeutics matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 63.4 M | |
| Cash And Short Term Investments | 352.3 M |
More Resources for Fulcrum Stock Analysis
A comprehensive view of Fulcrum Therapeutics starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Fulcrum Therapeutics Stock. Key reports that frame Fulcrum Therapeutics Stock are listed below:Historical Fundamental Analysis of Fulcrum Therapeutics can be used to cross-verify projections for Fulcrum Therapeutics. The historical series provides projection context. Our How to Invest in Fulcrum Therapeutics guide provides practical guidance on trading Fulcrum Stock.Analysis related to Fulcrum Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Understanding Fulcrum Therapeutics includes distinguishing between market value and book value, where book value reflects Fulcrum's accounting equity. Fulcrum Therapeutics' market capitalization is 509.49 M. A P/B ratio of 1.46 indicates the market values Fulcrum Therapeutics above its accounting book value. Enterprise value stands at 163.63 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Fulcrum Therapeutics' value from its trading price, which are computed with different methods. For Fulcrum Therapeutics, key inputs include a P/B ratio of 1.46, and ROE of -25.3%. By contrast, market price reflects the level where buyers and sellers transact.